Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 7:5:1194575.
doi: 10.3389/frph.2023.1194575. eCollection 2023.

Biological therapies for premature ovarian insufficiency: what is the evidence?

Melpomeni Moustaki  1 , Adamantia Kontogeorgi  2 , Gkalia Tsangkalova  2 , Haralampos Tzoupis  2 , Antonis Makrigiannakis  3 , Andromachi Vryonidou  1 , Sophia N Kalantaridou  2   4
Affiliations
Review

Biological therapies for premature ovarian insufficiency: what is the evidence?

Melpomeni Moustaki et al. Front Reprod Health. .

Abstract

Premature Ovarian Insufficiency (POI) is a multi-factorial disorder that affects women of reproductive age. The condition is characterized by the loss of ovarian function before the age of 40 years and several factors have been identified to be implicated in its pathogenesis. Remarkably though, at least 50% of women have remaining follicles in their ovaries after the development of ovarian insufficiency. Population data show that approximately up to 3.7% of women worldwide suffer from POI and subsequent infertility. Currently, the treatment of POI-related infertility involves oocyte donation. However, many women with POI desire to conceive with their own ova. Therefore, experimental biological therapies, such as Platelet-Rich Plasma (PRP), Exosomes (exos) therapy, In vitro Activation (IVA), Stem Cell therapy, MicroRNAs and Mitochondrial Targeting Therapies are experimental treatment strategies that focus on activating oogenesis and folliculogenesis, by upregulating natural biochemical pathways (neo-folliculogenesis) and improving ovarian microenvironment. This mini-review aims at identifying the main advantages of these approaches and exploring whether they can underpin existing assisted reproductive technologies.

Keywords: HRT; PRP; Premature Ovarian Insufficiency; biological therapies; exosomes; in vitro activation; microRNAs; stem cell therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA diagram describing the selection process for studies included.
Figure 2
Figure 2
Potential mechanisms for biological therapies in POI.
See this image and copyright information in PMC

References

    1. Lambrinoudaki I, Paschou SA, Lumsden MA, Faubion S, Makrakis E, Kalantaridou S, et al. Premature ovarian insufficiency: a toolkit for the primary care physician. Maturitas. (2021) 147:53–63. 10.1016/j.maturitas.2020.11.004 - DOI - PubMed
    1. Kalantaridou SN, Nelson LM. Premature ovarian failure is not premature menopause. Ann N Y Acad Sci. (2000) 900:393–402. 10.1111/j.1749-6632.2000.tb06251.x - DOI - PubMed
    1. Jankowska K. Premature ovarian failure. Menopausal Rev. (2017) 16(2):51–6. 10.5114/pm.2017.68592 - DOI - PMC - PubMed
    1. Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. (2016) 31(5):926–37. 10.1093/humrep/dew027 - DOI - PubMed
    1. Pastuszek E, Lukaszuk A, Kunicki M, Mockun J, Kloss G, Malinowska I, et al. New AMH assay allows rapid point of care measurements of ovarian reserve. Gynecol Endocrinol. (2017) 33(8):638–43. 10.1080/09513590.2017.1306735 - DOI - PubMed